FDA labs stay open
This article was originally published in The Tan Sheet
House Energy and Commerce Chairman John Dingell says an Aug. 17 decision by FDA to not proceed with reorganization plans that include closing seven of its field labs will maintain an "essential part of protecting consumers and ensuring the safety of our nation's food and drug supply." FDA has called off plans to close seven of its 13 labs as part of the Office of Regulatory Affairs reorganization it announced in March, Dingell and fellow Michigan Democrat Bart Stupak, Oversight and Investigation Subcommittee chairman, say in a release (1"The Tan Sheet" March 26, 2007, p. 5). The House has passed legislation with FDA's fiscal 2008 appropriations with an amendment from Stupak that prohibits the agency from using any of the funding to pay for closing its field labs or ORA district offices...
You may also be interested in...
FDA's decision to reorganize the Office of Regulatory Affairs will cause a "slow motion effect" for industry's interaction with FDA, according to a dietary supplement trade group executive
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.